anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a prospective, interventional, open-label, Early Feasibility Study Investigational Device Exemption (EFS-IDE). The Principal Investigator or research team member will consult a list of eligible patients based on predicted delivery dates and scheduled inductions. Women who are planning to undergo labor will be approached regarding this study. The study involves measurement of the fetal pulse signal with the investigational device, Lumerah, during labor. Lumerah is an investigational fetal pulse oximeter that measures fetal arterial oxygen saturation using safe, non-invasive, transabdominal near-infrared spectroscopy. The Lumerah device is intended as an adjunct to cardiotocography by detecting fetal oxygen deprivation that is both life-threatening to the fetus and can lead to the irreversibly debilitating consequences of newborn metabolic acidosis. The subjects will first undergo sonographic evaluation to assess distance from maternal skin to fetal tissue and to confirm fetal presentation and position during labor. The results of the sonographic measurements might influence the enrollment suitability of the subject as well as the placement of the Investigational device. The Oxiplex TS device, a non-ionizing laser system that provides researchers with valuable information regarding maternal optical tissue properties, will also be used. Once the membranes are ruptured, the investigator's team will use a Nellcor N-400 System with a sterile, single-use transvaginal sensor for data collection only. The outcomes of the fetal oxygenation measurements are masked; only the Sponsor is aware of the measurements. Therefore, no clinical decisions will be made based on the information derived from any of the devices used in this study.
PCT No. PCT/NL93/00220 Sec. 371 Date Aug. 7, 1995 Sec. 102(e) Date Aug. 7, 1995 PCT Filed Oct. 29, 1993 PCT Pub. No. WO90/03184 PCT Pub. Date Apr. 5, 1990The present invention relates to cultured cells of Quillaja sp. For the preparation of active substances from Quillaja sp., such as saponins. The cells may either originate from a callus tissue culture or from a suspension cell culture. Preferred Quillaja sp. are species selected from the group consisting of Quillaja saponaria Molina, Quillaja smegmadermos, Quillaja brasiliesis. The invention further relates to active substances extracted from cultured cells of Quillaja sp. and to preparations comprising these active substances, or a non-dialysable or a dialysable fraction thereof, to methods for preparing the active substances and to various agents, comprising the dialyzable and/or the non-dialysable fraction of an extract of cultured cells of Quillaja sp. And having various properties.
Subjects with Type 2 Diabetes Mellitus (T2DM). Subjects will receive AG and saline infusions, but the order of which they receive will be random and they will not be told which one they are receiving on each given visit. Arginine will be used at both study visits.
The invention relates to an anticancer drug combination containing antimetabolites; the anti-cancer drug combination includes anticancer active ingredients and pharmaceutical excipient and is characterized in that: the anticancer active ingredients are antimetabolites and antimetabolite synergistic agents selected from diclofenac ethamine drugs, taxol anticancer drugs and/or tetrazine compounds. The pharmaceutical excipient is mainly high molecular polymer which is biologically soluble, degradable and absorbable. The anticancer drug combination is mainly a slow-release implant or a slow-release injection. The slow-release injection is composed of slow-release micro-spheres and solvent, and the solvent is common solvent or special solvent containing a suspending agent. The suspending agent is selected from sodium carboxymethyl cellulose, mannite, and the like, and is used for suspending anticancer active ingredients or the slow-release particles or micro-spheres containing anticancer active ingredients to facilitate injection. By placing or injecting the slow-release formulation on tumors locally, not only is the systemic toxicity effect of drugs reduced, but also local drug concentration of tumor can be selectively raised and the curative effect of non-operative treatments such as chemotherapeutic drugs, radiation therapy, and the like, can be improved as well.
Arm A MDD participants will receive CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. The CYB003 dose received will depend on the cohort/time of enrollment. All MDD participants will receive supportive EMBARK psychotherapy throughout the study.
In the control condition, participants will receive a home exercise program on paper. The exercise program will be the conventionally prescribed one by the Andalusian Public Health Service. Participants will be told to perform exercises during a minimum of 4 week at home for at least 5 days per week, starting after baseline measurement.
In particular the present invention relates to a non-steroidal sulphamate compound. Over the past two decades, considerable interest has been in the development of inhibitors of the aromatase pathway which converts the androgen precursor androstenedione to oestrone. However, there is evidence that oestrone sulphatase (E1-STS) pathway, i.e. the hydrolysis of oestrone sulphate to oestrone (E1S to E1), as opposed to the aromatase pathway, is the major source of oestrogen in breast tumours. The compound is suitable for use as an inhibitor of oestrone sulphatase. The compound has a polycyclic ring structure comprising two or more rings wherein at least two of the rings mimic the A and B rings of oestrone. Preferably the compound has general formula (A), wherein R1-R6 are independently selected from H, halo, hydroxy, sulphamate, alkyl and substituted variants or salts thereof; by wherein at least one of R1-R6 is a sulphamate group; and wherein the polycyclic ring structure is not tetrahydro-naphthol. Or preferably the compound of general formula (B), wherein R1-R6 are independently selected from H, halo, hydroxy, sulphamate, alkyl and substituted variants or salts thereof; but wherein at least one of R1-R6 is a sulphamate group; and wherein two or more of R1-R6 are linked together to form an additional cyclic structure.
Ten subjects will be randomly assigned at a 4: 1 ratio to receive either single dose of 80 μg PA9159 or placebo. There will be a one week follow-up period to review all available clinical and laboratory safety data.
To evaluate A) the feasibility of recruiting eligible subjects into a randomized trial of a culture-directed versus empiric antibiotic strategy for patient-reported UTI symptoms in older women and B) the adherence to study procedures. We will recruit and enroll women with a history of rUTI from the Women's Center for Bladder and Pelvic Health and the University of Pittsburgh's Clinical and Translational Science Institute (CTSI) Pitt+Me® Research Registry. Once enrolled and randomized, women will be followed for a total of 28 days to document both clinical resolution at day 7 from symptom onset and adverse events. H1) Enrolling a total of 70 subjects in \<1 year (at least 10% of eligible patients) will demonstrate feasibility of recruitment and H2) Documenting at least 70% patient compliance with study procedures will confirm patient adherence to study protocol. Exploratory Aim: To explore the safety of a culture-directed UTI treatment strategy and preliminary secondary outcomes of assigned treatments. H1) There will be an overall low number of adverse events and H2) Preliminary outcome data will help power future trial.
In Group A (intervention), the 12 participants will form 2 groups (6 participants per group) according to their individual exercise intensity levels determined prior to the intervention for each participant. Each group will receive online coach-supervised training sessions 3 times per week for 4 weeks (a total of 12 sessions), which will be delivered by a certified coach and an assistant (a student helper, major in sports and health). Each session will consist of warm-up, aerobic exercise, resistance exercise, stretching and cool-down, with exercise period progressively increasing from 30 minutes to 50 minutes and exercise intensity progressively increasing from low to moderate levels (Table 1). Lighter intensity may be adopted when there is a need (e.g., for those with severe conditions). Target heart rate during exercise will be monitored by a pulse oximeter. Cameras will be requested to be turned on all the time.
OBJECTIVE: To evaluate hemostatic efficacy, complications, and subsequent pregnancy outcomes in women with placenta previa who underwent combined vertical compression sutures in the lower uterine segment and intrauterine balloon tamponade (Hot-Dog method) to achieve hemostasis after cesarean section.
METHODS: We retrospectively reviewed data for 117 women with singleton pregnancy diagnosed with placenta previa who underwent cesarean section between 29 and 38 weeks' gestation. Treatments were as follows: (1) conventional-intravenous oxytocin administration after placental detachment and suturing of bleeding points at the detachment site as needed (conventional group) (n = 47). (2) Intrauterine balloon tamponade alone (balloon group) (n = 41). (3) Vertical compression sutures + intrauterine balloon tamponade (Hot-Dog group) (n = 29).
RESULTS: The placenta accreta spectrum prevalence was significantly higher in the balloon and Hot-Dog groups versus the conventional group. The prevalence of anteriorly located placenta was significantly higher in the Hot-Dog versus balloon groups. Intraoperative and total blood loss were significantly higher in the Hot-Dog versus conventional groups. Postoperative blood loss was significantly lower in the Hot-Dog versus balloon groups. Fewer additional procedures for managing postoperative hemorrhage were required in the Hot-Dog versus conventional and balloon groups. The number of subsequent pregnancies in the conventional, balloon, and Hot-Dog groups was 11 (23.4%), 8 (19.5%), and 4 (13.8%), respectively; all resulted in live births at term without serious obstetric complications.
CONCLUSION: The Hot-Dog method is a straightforward and safe hemostasis technique for placenta previa that preserves fertility and controls severe bleeding.
Tea (Camellia sinensis [L.] O. Kuntze) is cultivated as a beverage crop. Despite being a hardy perennial, the tea plant is susceptible to various biotic stresses. Among them, the foliar disease blister blight (BB) is considered the most serious threat to the tea industry, particularly in Asia. BB caused by Exobasidium vexans (Basidiomycetes) was first reported from Northern India in 1868 and gradually established in other tea-growing countries. The fungus E. vexans attacks young harvestable shoots and causes 20 to 50% crop loss. Over the past 150 years, scientific research has delved into various aspects of BB disease, including pathogen biology, disease cycle, epidemiology, disease forecasting, crop loss assessment, and disease management strategies. In a recent shift in research focus, scientists have begun to investigate the resistance mechanisms of tea plants against BB and apply this knowledge to commercial tea cultivation. Although progress has been significant in understanding the fundamental aspects of BB resistance, the detailed molecular mechanisms driving this resistance remain under investigation. This paper focuses on the current understanding of defense mechanisms employed by tea plants against E. vexans and, conversely, how E. vexans overcomes these defenses. Furthermore, we discuss the application of plant resistance strategies in commercial tea cultivation. Lastly, we identify existing research gaps and propose future research directions in the field.
OPANA ER contains oxymorphone, which is a controlled substance. Oxymorphone is controlled under Schedule II of the Controlled Substances Act. Oxymorphone, like all opioids, is liable to diversion and misuse and should be handled accordingly. Patients and their families should be instructed to flush any OPANA ER tablets that are no longer needed.

OPANA ER may be targeted for theft and diversion. Healthcare professionals should contact their State Medical Board, State Board of Pharmacy or State Control Board for information on how to detect or prevent diversion of this product.

Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). [See USP Controlled Room Temperature].

Dispense in tight container as defined in the USP, with a child-resistant closure (as required).
The present invention provides chitosan microsphere or microcapsule drug carriers with a uniform dimension and stable dispersibility for protein drugs, polypeptide drugs, anticancer drugs, hormone drugs and other hydrophilic drugs and oil soluble drugs, and the chitosan microsphere or microcapsule drug carriers are used for the controlled release and target administration, etc. of the hydrophilic drugs. The drug carriers are characterized in that the chitosan microsphere or microcapsule drug carriers with a uniform dimension and stable dispersibility are prepared by two methods: (1). one method comprises the following steps: dissolving the hydrophilic drugs in the acetic acid water solution of chitosan, pressing the water phase in an oil phase through microporous membranes by pressure to obtain emulsion drops with a uniform dimension; then solidifying the emulsion drops with a certain solidification method; (2). the other method comprises the following steps: dissolving the oil soluble drugs in an oily solvent, and the hydrophilic drugs in the acetic acid water solution of chitosan to prepare a primary emulsion O1/W by using a homogeneous phase emulsifier; pressing the primary emulsion in an oil phase through microporous membranes by pressure to obtain multiple emulsion drops (O1/W)/O2 with a uniform dimension; then solidifying the multiple emulsion drops with a certain solidification method. Under optimum conditions, the diameter distribution coefficient of the microspheres and the microcapsules can be controlled within 11%, and the diameter can be freely controlled from 1 to 100 micrometers; the technology solves the problems of non-uniform grain diameters, low embedding rate and poor dispersibility of the chitosan drug carriers prepared with the traditional agitation emulsification method, and has the prospects of solving the critical problems of stable drug release and in vivo utilization rate improvement of the drugs by utilizing the characteristic of uniform.
PURPOSE:The titled capsule, obtained by dispersing or dissolving an acting substance in the wall part, and containing only a gas in the core part, having a prolonged contact time of the acting substance and a mucous membrane, capable of improving the remedial effect, and suitable to medicines for the oral cavity and cavity of pharynx. CONSTITUTION:A soft gelatin capsule containing an acting substance, e.g. an ether oil of astringent tincture in the dispersed or dissolved state in the wall part and only a gas in the core part, and consisting of preferably 40-50% gelatin, 20-30% glycerol and 20-30% water, used as the above-mentioned medicines. The above-mentioned capsule is capable of bringing the acting substance into contact with the mucous membrane in the mouth for a long time with the high adhesiveness of the gelatin to the mucous membrane though the capsule is a simple pharmaceutical form, and suitable for both liquid and solid pharmaceuticals. The acting substance can be uniformly released without irritation, and no adjuvant substance having caries accelerating action, e.g. a saccharide, is contained.
Safety and effectiveness in children under 12 years of age have not been demonstrated. Therefore, the use of Tenex in this age group is not recommended. There have been spontaneous postmarketing reports of mania and aggressive behavioral changes in pediatric patients with attention-deficit hyperactivity disorder (ADHD) receiving Tenex. The reported cases were from a single center. All patients had medical or family risk factors for bipolar disorder. All patients recovered upon discontinuation of guanfacine HCl. Hallucinations have been reported in pediatric patients receiving Tenex for treatment of attention-deficit hyperactivity disorder.
PURPOSE: PPAR alpha, gamma, and delta active materials using Dendropanax morbifera Lev. leaves are provided to prevent or treat diseases such as obesity, diabetes, hyperlipidemia, hypertension, atherosclerosis, cardiovascular diseases, metabolic diseases, cancer, and inflammation, and to be used as a main ingredient of a pharmaceutical product, a functional food, and a health food. CONSTITUTION: A method for isolating PPAR alpha, gamma, and delta active materials using Dendropanax morbifera Lev. leaves comprises: a step of extracting Dendropanax morbifera Lev. leaves with hydrous alcohol and preparing concentrate(S101); and a step for fractioning the concentrate with a non-polar solvent(S103). The PPAR alpha, gamma, and delta active materials contain a Dendropanax morbifera Lev. leaf extract and a fraction thereof. The PPAR alpha, gamma, and delta active materials further contains a pharmaceutically acceptable inactive carrier. The inactive carrier is selected from a group consisting of starch and lactose. [Reference numerals] (AA) Start; (BB) End; (S101) Concentration step of extracting Dendropanax morbifera Lev. leaves with hydrous alcohol and preparing concentrate; (S103) Fraction preparing step for fractioning the concentrate obtained from the concentration step with a non-polar solvent
Pain associated with orthodontic treatment is one of the main causes of treatment discontinuation and patient non-cooperation. Several treatment modalities have been studied to alleviate orthodontic pain which includes pharmacological, mechanical, and behavioral approach. One potential treatment is the application of photobiomodulation (PBM) therapy which is a form of light therapy. The objective of this study is to determine to effect of PBM therapy in adult patients undergoing clear aligners orthodontic treatment. This effect will be evaluated by recording the pain on visual analog scale given to the patients before the placement of clear aligners and collecting saliva. The patients will be provided with active PBM Ortho device and sham PBM device (placebo, which will look similar to the active device) to use them at home for one 8 minutes application for 7 days (4 minutes per arch, upper or lower). The pain scale sheets will also be given to the patients to fill them every day for 7 days. The inflammatory protein associated with pain present in the saliva will be collected on Day 1 (24 hours after clear aligner treatment start), Day 4 (fourth day of treatment), and Day 7 (after 1 week from the treatment start). On the last visit, the device and pain scale sheets will be collected from the patients. If successful, this device therapy will reduce the orthodontic associated pain and improve patients' compliance and cooperation.
Babies who were born with congenital clubfeet are currently being treated by the conventional Ponseti method. This procedure is done in an outpatient clinic setup. The procedure is painless but may cause some discomfort to the patient. This study will examine the use of 5 CC Sucrose solution as a comforting agent for the babies. The control group will consist of patients who will get 5cc saline pre cast application, while the study group will be given 5cc of Sucrose solution. Patients and physicians are blinded to the treatment they get. Outcome measures will include pulse rate and oxygenation as an accepted measure of discomfort.
PURPOSE:To purify a rheumatoid-specific protein useful for the diagnosis of rheumatoid arthritis and separated from rheumatoid serum, easily in a short time, in high purity, by using an anti-rheumatoid-specific protein antibody. CONSTITUTION:A fraction reactive with anti-rheumatoid-specific protein is recovered from a raw material containing rheumatoid-specific protein (e.g. protein mixture such as plasma, serum, etc.) to effect the purification of the rheumatoid-specific protein. Concretely, an anti-rheumatoid-specific protein is bonded to a gel such as sephalose 4B, and passed through a column (affinity column) packed with said gel. The adsorbed rheumatoid-specific protein is separated from the gel according to conventional method to elute the adsorbed protein from an affinity gel, and the recovered protein is purified. A high-purity rheumatoid-specific protein can be prepared easily in a short time.
<P>PROBLEM TO BE SOLVED: To provide a device and method for the delivery of halogenated ethers for producing analgesia in a patient, related to the field of analgesia and conscious sedation.  <P>SOLUTION: Inhalant anesthetics are developed with a number of properties including rapid onset and recovery, controllability, and an ideally broad safety profile. The efficacy of these agents is measured by their ability to create anesthesia within the framework of the other desirable properties. The instant invention focuses on the dosage level where analgesia occurs but amnesia or lack of consciousness does not. In addition to identifying the dosage level where pain is sharply reduced or eliminated but awareness remains, a delivery system for safe and effective delivery of the agent is described.  <P>COPYRIGHT: (C)2011,JPO&INPIT
PURPOSE:To obtain a medical cosmetic having excellently promoting action on growth of hair, high safety and low irritation to the skin. CONSTITUTION:The medicinal cosmetic contains 0.001-10wt.% extract of Hypericum erectum thumb. and carbon dioxide gas, having pH >=7, especially pH 4.5-6.5. The medical cosmetic is prepared by charging a pressure container with components except carbon dioxide gas and sealing a high-pressure carbon dioxide gas into the pressure container, adding dry ice pellets to a pressure container and sealing or charging the pressure container with a component except carbon dioxide gas contained in a carbonate such as sodium hydrogencarbonate and adding a pH adjuster to evolve carbon dioxide gas, namely sealing method. Carbon dioxide gas is partly dissolved in the medicinal cosmetic whole partly exists as gas in the container. The concentration of carbon dioxide gas contained is preferably >=60ppm and carbon dioxide gas is preferably injected in the container to make 1.2-8kg/cm<2> gauge-pressure in the container at 35 deg.C.
The present invention relates to a solomonseal rhizome agglutinin II protein which is prepared from stem tubers of solomonseal rhizome as raw materials. A preparation process orderly comprises the steps of the preparation of a crude product, the separation and the purification of affinity columns and the purification of molecular sieves. In the separation and the purification of affinity columns, mannose-Sepharose4B is used as an affinity absorbent, and mannose solution is used for desorption. The molecular sieves are SephacrylS-100 columns. After affinity chromatography samples dissolved by normal salt solution are dialyzed to equilibrium, the samples are applied to the columns. The samples on the columns are eluted by the normal salt solution and are partially collected. After the detection of ultraviolet absorption and detection activity at the position of 280 nm, active components are collected. The dialyzed and desalted active components are frozen and dried, and the purified solomonseal rhizome agglutinin II protein is obtained. With ACV as a positive control medicine, the present invention uses a CPE method and an MTT method to study the activity of the solomonseal rhizome agglutinin II protein for resisting herpes simplex viruses (HSV). The present invention proves that the solomonseal rhizome agglutinin II protein has strong inhibiting effect on human herpes simplex viruses, which is helpful to develop a new medicine.